(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of 11.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.71%.
Septerna's revenue in 2026 is $45,951,000.On average, 10 Wall Street analysts forecast SEPN's revenue for 2026 to be $3,383,830,000, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $6,082,568,358. On average, 10 Wall Street analysts forecast SEPN's revenue for 2027 to be $3,082,642,950, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $5,799,658,202.
In 2028, SEPN is forecast to generate $2,920,486,033 in revenue, with the lowest revenue forecast at $1,540,288,628 and the highest revenue forecast at $3,772,135,416.